ISPOR - PMS81 Cost-Effectiveness and Budget Impact of Certolizumab Pegol Against a Mix of Treatments in an Outcomes-Based Risk-Sharing Scheme in Finland

Full Text

PMS81 Cost-Effectiveness and Budget Impact of Certolizumab Pegol Against a Mix of Treatments in an Outcomes-Based Risk-Sharing Scheme in Finland

Abstract

Authors

C. Asseburg E.J. Soini M. Taiha

Back to Volume 15, Issue 7

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now